PharmaCom BioVet, Inc. (PHMB)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
PharmaCom BioVet, Inc. (PHMB) with AI Score 52/100 (Hold). PharmaCom BioVet, Inc. operates a network of companion animal cancer treatment centers in the United States, focusing on advanced procedures like bone marrow transplantation. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026PharmaCom BioVet, Inc. (PHMB) Healthcare & Pipeline Overview
PharmaCom BioVet, Inc. specializes in companion animal cancer treatment centers, offering advanced procedures and proprietary technologies. Operating in the niche veterinary oncology market, the company focuses on bone marrow transplantation and innovative therapies for pets with cancer, distinguishing itself through specialized care and licensed compounds.
Investment Thesis
PharmaCom BioVet, Inc. presents a high-risk, high-reward investment profile, primarily due to its presence in the OTC market and focus on a niche sector within veterinary medicine. The company's potential lies in its specialized treatment offerings, including bone marrow transplantation and proprietary compounds for companion animal cancer. Success hinges on the effective commercialization and adoption of these advanced treatments. Key value drivers include the expansion of its treatment center network and successful clinical outcomes demonstrating the efficacy of its licensed technologies. However, the company's OTC listing indicates higher volatility and potential liquidity challenges. Investors should closely monitor regulatory developments, market acceptance of its treatments, and the company's ability to secure funding for ongoing operations and expansion. Given the absence of a dividend and a negative beta of -6.74, investment decisions should be made with a clear understanding of the speculative nature of the stock and the potential for significant price fluctuations.
Based on FMP financials and quantitative analysis
Key Highlights
- PharmaCom BioVet, Inc. focuses on operating a network of companion animal cancer treatment centers in the United States.
- The company specializes in bone marrow transplantation and other advanced cancer treatment procedures for companion animals.
- PharmaCom BioVet has licensed a series of proprietary devices and compounds aimed at reducing suffering in animals with cancer.
- The company was formerly known as ABV Gold Inc. and changed its name to PharmaCom BioVet, Inc. in August 2008.
- PharmaCom BioVet, Inc. is headquartered in Raleigh, North Carolina.
Competitors & Peers
Strengths
- Specialized expertise in veterinary oncology.
- Proprietary devices and compounds for cancer treatment.
- Established network of treatment centers.
- Focus on bone marrow transplantation.
Weaknesses
- Small market capitalization.
- Limited financial resources.
- Dependence on proprietary technologies.
- OTC market listing indicates higher risk.
Catalysts
- Potential expansion of treatment center network in the next 1-2 years.
- Development and commercialization of proprietary cancer treatment technologies.
- Strategic partnerships with veterinary clinics to expand service reach.
Risks
- Limited financial resources may hinder growth and development.
- Competition from established veterinary practices and pharmaceutical companies.
- Regulatory hurdles for new cancer treatment technologies.
- OTC market listing indicates higher volatility and risk.
- Economic downturn affecting pet owner spending on specialized veterinary care.
Growth Opportunities
- Expansion of Treatment Centers: PharmaCom BioVet has the opportunity to expand its network of companion animal cancer treatment centers across the United States. The market for specialized veterinary oncology services is growing, driven by increased pet ownership and a willingness among owners to invest in advanced medical care for their pets. Expanding the geographic footprint of its treatment centers would allow PharmaCom BioVet to reach a larger customer base and increase revenue. This expansion could be achieved through acquisitions, partnerships, or the development of new facilities, with a potential timeline of 3-5 years.
- Development of Proprietary Technologies: PharmaCom BioVet can further develop and commercialize its portfolio of proprietary devices and compounds for cancer treatment in companion animals. Investing in research and development to enhance the efficacy and safety of these technologies could create a competitive advantage and attract more customers. Successful development and regulatory approval of new products could significantly increase the company's revenue and market share. The timeline for this growth opportunity is dependent on R&D progress and regulatory pathways, potentially spanning 2-5 years.
- Strategic Partnerships with Veterinary Clinics: PharmaCom BioVet can establish strategic partnerships with general veterinary clinics to offer specialized oncology services to their clients. These partnerships would allow the company to leverage the existing infrastructure and customer base of established veterinary practices, expanding its reach without the need for significant capital investment. By providing specialized expertise and treatment options, PharmaCom BioVet can enhance the services offered by partner clinics and generate additional revenue. The timeline for establishing these partnerships could be within 1-3 years.
- Focus on Bone Marrow Transplantation: PharmaCom BioVet's specialization in bone marrow transplantation for companion animals presents a significant growth opportunity. As one of the few providers of this advanced treatment, the company can capitalize on the increasing demand for specialized cancer care for pets. Promoting its expertise in bone marrow transplantation and demonstrating successful outcomes could attract referrals from other veterinary practices and pet owners seeking advanced treatment options. The timeline for this growth opportunity is ongoing, with continuous efforts to refine and promote its expertise in this area.
- Telemedicine and Remote Consultations: PharmaCom BioVet can leverage telemedicine and remote consultation services to expand its reach and provide convenient access to its expertise. Offering remote consultations with veterinary oncologists can attract pet owners who may not have access to specialized treatment centers in their local area. Telemedicine can also facilitate follow-up care and monitoring of patients after treatment. Implementing telemedicine services can enhance customer satisfaction and generate additional revenue streams. The timeline for implementing and scaling telemedicine services could be within 1-2 years.
Opportunities
- Expansion of treatment center network.
- Development of new proprietary technologies.
- Strategic partnerships with veterinary clinics.
- Increasing demand for advanced veterinary care.
Threats
- Competition from established veterinary practices.
- Regulatory hurdles for new treatments.
- Economic downturn affecting pet owner spending.
- Potential for technological obsolescence.
Competitive Advantages
- Specialized Expertise: Focus on bone marrow transplantation and advanced cancer treatments creates a niche expertise.
- Proprietary Technologies: Licensed devices and compounds provide a competitive advantage.
- Established Network: Operating a network of treatment centers offers a physical presence and brand recognition.
- First-Mover Advantage: Early focus on veterinary oncology positions the company ahead of general veterinary practices.
About PHMB
PharmaCom BioVet, Inc., formerly ABV Gold Inc., was incorporated in 1995 and rebranded in 2008 to focus on veterinary oncology. Headquartered in Raleigh, North Carolina, the company operates a network of specialized treatment centers for companion animals diagnosed with cancer. PharmaCom BioVet's core mission is to provide advanced cancer care, including bone marrow transplantation, for pets suffering from lymphoma and other incurable diseases. The company has licensed a series of proprietary devices and compounds designed to alleviate suffering and improve treatment outcomes in animals with cancer. PharmaCom BioVet distinguishes itself by focusing on innovative treatment procedures and technologies within the veterinary healthcare market. Its services cater to pet owners seeking advanced cancer care options beyond traditional veterinary practices. The company's strategic focus on bone marrow transplantation and proprietary compounds positions it as a specialized provider in the growing field of veterinary oncology. By offering these advanced treatments, PharmaCom BioVet aims to address a critical need in the market for comprehensive cancer care for companion animals, setting it apart from more general veterinary service providers. While the market cap is currently $0, the company's focus on specialized treatments and proprietary technologies may offer potential for future growth and expansion within the veterinary healthcare sector. The company's ability to successfully develop and commercialize its licensed devices and compounds will be crucial to its long-term success and market positioning.
What They Do
- Operates a network of companion animal cancer treatment centers in the United States.
- Focuses on developing bone marrow transplantation procedures for companion animals.
- Provides cancer treatment for pets diagnosed with lymphoma and other cancers.
- Licenses proprietary devices and compounds to reduce suffering in animals with cancer.
- Offers advanced cancer care options beyond traditional veterinary practices.
- Specializes in treating diseases that are otherwise considered incurable in pets.
Business Model
- Generates revenue by providing cancer treatment services at its network of treatment centers.
- Licenses proprietary devices and compounds to other veterinary practices.
- Offers specialized procedures such as bone marrow transplantation.
- Caters to pet owners seeking advanced cancer care for their companion animals.
Industry Context
PharmaCom BioVet, Inc. operates within the veterinary healthcare market, specifically targeting the oncology segment. This market is experiencing growth due to increased pet ownership and rising demand for advanced medical treatments for animals. The competitive landscape includes general veterinary practices, specialized veterinary oncology centers, and pharmaceutical companies developing veterinary cancer drugs. PharmaCom BioVet differentiates itself by focusing on bone marrow transplantation and proprietary devices, positioning it as a specialized provider within this expanding market. Success depends on its ability to effectively market its services and demonstrate superior treatment outcomes compared to competitors.
Key Customers
- Pet owners seeking advanced cancer treatment options for their companion animals.
- Veterinary clinics referring patients for specialized oncology services.
- Owners of pets diagnosed with lymphoma, cancer, and other incurable diseases.
- Individuals willing to invest in advanced medical care for their pets.
Financials
Chart & Info
PharmaCom BioVet, Inc. (PHMB) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Monday
· Feb 3, 2020
-
Stocks That Hit 52-Week Lows On Friday
· Dec 20, 2019
-
Stocks That Hit 52-Week Lows On Tuesday
· Dec 10, 2019
-
Stocks That Hit 52-Week Lows Of Monday
· Oct 7, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PHMB.
Price Targets
Wall Street price target analysis for PHMB.
MoonshotScore
What does this score mean?
The MoonshotScore rates PHMB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Ira Frohman
CEO
Ira Frohman serves as the Chief Executive Officer of PharmaCom BioVet, Inc. His background includes experience in managing and growing companies, with a focus on strategic development and operational efficiency. He has been involved in various aspects of the company's operations, from overseeing the development of proprietary technologies to managing the expansion of the treatment center network. His expertise spans across business development, financial management, and strategic planning.
Track Record: Under Ira Frohman's leadership, PharmaCom BioVet has focused on expanding its network of companion animal cancer treatment centers and developing proprietary devices and compounds for cancer treatment. Key milestones include securing licenses for innovative technologies and establishing strategic partnerships to enhance the company's market presence. His leadership has been instrumental in guiding the company's strategic direction and navigating the challenges of the veterinary healthcare market.
PHMB OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that PharmaCom BioVet, Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited trading volume and may not provide regular financial reporting, increasing the risk for investors. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, resulting in less transparency and potentially higher volatility. This tier is often associated with speculative investments and requires careful due diligence.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Liquidity: Low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- Lack of Transparency: Unknown disclosure status and potential shell risk increase the risk of fraud or mismanagement.
- Regulatory Uncertainty: OTC-listed companies face less regulatory oversight, increasing the risk of non-compliance.
- Market Volatility: OTC markets are generally more volatile than major exchanges, leading to significant price fluctuations.
- Limited Information: Difficulty in obtaining reliable financial information makes it challenging to assess the company's value.
- Verify the company's legal standing and registration.
- Investigate the background and experience of the management team.
- Assess the company's financial health and review available financial statements.
- Evaluate the company's business model and competitive landscape.
- Check for any legal or regulatory issues.
- Determine the company's ownership structure and identify any potential conflicts of interest.
- Consult with a financial advisor before investing.
- Focus on a specific niche market (veterinary oncology).
- Proprietary technologies and licensed compounds.
- Established network of treatment centers.
- CEO with relevant experience in business development.
What Investors Ask About PharmaCom BioVet, Inc. (PHMB) — Healthcare
What does PharmaCom BioVet, Inc. do?
PharmaCom BioVet, Inc. operates a network of companion animal cancer treatment centers in the United States. The company specializes in providing advanced cancer care for pets, including bone marrow transplantation and other specialized procedures. It focuses on developing and licensing proprietary devices and compounds aimed at reducing suffering and improving treatment outcomes for animals diagnosed with cancer and other incurable diseases. The company targets pet owners seeking specialized oncology services beyond traditional veterinary care.
What do analysts say about PHMB stock?
Currently, there is no available analyst coverage for PHMB stock due to its OTC listing and small market capitalization. The stock's performance is subject to market speculation and company-specific developments. Investors should conduct their own due diligence and consider the risks associated with investing in OTC-listed companies. Key valuation metrics are not readily available, and growth considerations depend on the company's ability to successfully commercialize its technologies and expand its treatment center network.
What are the main risks for PHMB?
The main risks for PharmaCom BioVet, Inc. include its OTC market listing, which indicates higher volatility and limited liquidity. The company's small market capitalization and limited financial resources pose challenges to its growth and development. Competition from established veterinary practices and pharmaceutical companies also presents a significant risk. Regulatory hurdles for new cancer treatment technologies and potential economic downturns affecting pet owner spending could further impact the company's performance. The unknown disclosure status adds another layer of risk.
What are the key factors to evaluate for PHMB?
PharmaCom BioVet, Inc. (PHMB) currently holds an AI score of 52/100, indicating moderate score. Key strength: Specialized expertise in veterinary oncology. Primary risk to monitor: Limited financial resources may hinder growth and development. This is not financial advice.
How frequently does PHMB data refresh on this page?
PHMB prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven PHMB's recent stock price performance?
Recent price movement in PharmaCom BioVet, Inc. (PHMB) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized expertise in veterinary oncology. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider PHMB overvalued or undervalued right now?
Determining whether PharmaCom BioVet, Inc. (PHMB) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying PHMB?
Before investing in PharmaCom BioVet, Inc. (PHMB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company profile and limited financial data.
- OTC market data may be less reliable than major exchange data.
- AI analysis is pending and may provide further insights.